Analytical Data
-
Gene name
CCT6A
- Application
-
Alternative Names
Acute morphine dependence-related protein 2 CCT-zeta-1 HTR3 Tcp20
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P40227
-
Expression Region
2-531aa
-
Molecular Weight
61.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCT6A, a member of the chaperonin family, plays a crucial role in protein folding and assembly within the cellular environment. Research has increasingly focused on its significance in various biological processes, including cell cycle regulation, stress response, and differentiation. The importance of CCT6A is underscored by its involvement in the stabilization and proper conformation of several client proteins, which are essential for maintaining cellular homeostasis. Abnormalities in CCT6A expression or function have been linked to a range of diseases, including cancer, where it is often found to be overexpressed, contributing to the survival and proliferation of cancer cells. Consequently, understanding the structure and function of CCT6A, along with its interaction networks, is imperative for uncovering potential therapeutic targets. Recent advancements in recombinant protein technologies have enabled the production of CCT6A in vitro, facilitating detailed studies on its biochemical properties and functional mechanisms. By investigating CCT6A through recombinant protein technology, researchers aim to elucidate its role in cellular processes and its potential implications in disease, paving the way for novel intervention strategies in health and disease management.
